Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children’s Oncology Group AHOD1331

Belsky JA, Renfro LA, Keller FG, Hodgson DC, Punnett A, McCarten K, Cho SY, Wu Y, Kelly KM, Castellino SM, Schwartz CL. Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children’s Oncology Group AHOD1331. Pediatr Blood Cancer. 2025 Jun 14:e31856. doi: 10.1002/pbc.31856. Epub ahead of print. PMID: 40515508; PMCID: PMC12230980.

CHIPS (Childhood Hodgkin International Prognostic Score), a predictive score for event-free-survival (EFS), was originally developed using factors presenting at diagnosis in patients with intermediate-risk Hodgkin lymphoma (HL). Prospective validation of CHIPS in patients was a pre-specified aim of AHOD1331, a trial comparing brentuximab-vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (Bv-AVEPC) to standard ABVE-PC (and response-adapted radiation) in children with high-risk HL.